Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference
Moleculin Biotech, Inc. (Nasdaq: MBRX) will participate in the Virtual Investor 2022 Top Picks Conference on January 27, 2022, at 9:00 AM ET, led by CEO Walter V. Klemp. The event will feature a corporate presentation and a moderated Q&A session where attendees can submit questions live or in advance. A live video webcast of the presentation will be available on the Company's website, followed by a replay for one year. Moleculin focuses on drug candidates for highly resistant tumors, including its lead program, Annamycin, for acute myeloid leukemia and soft tissue sarcoma.
- None.
- None.
HOUSTON, Jan. 20, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Klemp, Founder, President, CEO and Chairman, will participate in the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 9:00 AM ET.
As part of the virtual event, the Company will provide a corporate presentation, followed by a moderated interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to be noncardiotoxic and to avoid multidrug resistance mechanisms. In addition, Annamycin has been shown in animal models to reach higher concentration levels than doxorubicin (a leading anthracycline) in certain key organs, such as the lungs, liver and pancreas considered to be difficult-to-reach "sanctuary sites" for tumors. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-biotech-inc-to-present-at-the-virtual-investor-2022-top-picks-conference-301464936.html
SOURCE Moleculin Biotech, Inc.
FAQ
What is the date and time for Moleculin's presentation at the Virtual Investor Conference?
Who will be presenting on behalf of Moleculin Biotech at the conference?
How can I access the live video webcast of Moleculin's presentation?
What key topics will Moleculin discuss during the conference?
Will there be an opportunity to ask questions during the Moleculin presentation?
